reports
Merit Medical Reports Results for First Quarter Ended March 31, 2024
Merit Medical Reports Results for First Quarter Ended March 31, 2024 Q1 2024 reported revenue of $323.5 million, up 8.7% compared to Q1 2023Q1 2024 constant currency revenue* up 9.3% compared to Q1 2023Q1 2024 constant currency revenue, organic* up 7.0% compared to Q1 2023Q1 2024 GAAP operating margin of 11.1%, compared to 8.9% in Q1 2023Q1 2024 non-GAAP operating margin* of 17.3%, compared to 16.1% in Q1 2023Q1 2024 GAAP EPS $0.48, up 35.5%, compared to $0.36 in Q1 2023Q1 2024 non-GAAP EPS* $0.77, up 18.7%, compared to $0.64 in Q1 2023 * Constant currency revenue; constant currency revenu...
Merit Medical Launches the Micro ACE™ Advanced Micro-Access System
Merit Medical Launches the Micro ACE™ Advanced Micro-Access System Micro ACE combines a unique balance of stiffness and resiliency to achieve successful micro-access in challenging cases SOUTH JORDAN, Utah, March 19, 2024 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a global leader of healthcare technology, today announced commercial release of its US Food and Drug Administration (FDA)-cleared Micro ACE Advanced Micro-Access System. Merit also intends to file Micro ACE for CE mark designation. The Micro ACE system is the latest innovation in the Merit Vascular port...
Merit Medical Systems to Announce First Quarter 2024 Results on April ...
Merit Medical Systems to Announce First Quarter 2024 Results on April 30, 2024 SOUTH JORDAN, Utah, March 18, 2024 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a leading global manufacturer and marketer of healthcare technology, announced today that it will release its financial results for the quarter ended March 31, 2024, after the close of the stock market on Tuesday, April 30, 2024. Merit will hold its investor conference call on the same day (Tuesday, April 30, 2024) at 5:00 p.m. Eastern (4:00 p.m. Central, 3:00 p.m. Mountain, and 2:00 p.m. Pacific). To access the...
Merit Medical to Host Evening of Innovation during the 2024 Society of...
Merit Medical to Host Evening of Innovation during the 2024 Society of Interventional Radiology (SIR) Annual Scientific Meeting Merit Medical to host SIR attendees at Salt Lake City headquarters and SIR booth 320 SOUTH JORDAN, Utah, March 05, 2024 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a global leader of healthcare technology, announced today a series of events for clinicians attending the 2024 SIR Annual Meeting. These educational events will take place at Merit’s headquarters and at SIR booth 320. On March 26, Merit will host an Evening of Innovation ...
Merit Medical Introduces “Continued Growth Initiatives” Program and Fi...
Merit Medical Introduces “Continued Growth Initiatives” Program and Financial Targets for Three-Year Period Ending December 31, 2026 SOUTH JORDAN, Utah, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a leading global manufacturer and marketer of healthcare technology, today introduced its Continued Growth Initiatives Program and related financial targets for the three-year period ending December 31, 2026. Merit’s new multi-year financial targets are: Total revenue increase at a compound annual growth rate (CAGR) of 5% to 7% on an organic, cons...
Merit Medical Reports Results For Fourth Quarter and Year Ended Decemb...
Merit Medical Reports Results For Fourth Quarter and Year Ended December 31, 2023 - Issues Fiscal Year 2024 Guidance Q4 2023 reported revenue of $324.5 million, up 10.6% year-over-yearQ4 2023 constant currency revenue* up 10.3% year-over-yearQ4 2023 constant currency revenue, organic* up 8.3% year-over-yearQ4 2023 GAAP operating margin of 10.4%, compared to 10.4% in Q4 2022Q4 2023 non-GAAP operating margin* of 18.2%, compared to 17.8% in Q4 2022Q4 2023 GAAP EPS $0.47, compared to $0.58 in Q4 2022Q4 2023 non-GAAP EPS* $0.81, compared to $0.79 in Q4 2022Issues fiscal year 2024 financial guida...
Merit Medical Receives FDA 510(k) Clearance for SCOUT® MD™ Surgical Gu...
Merit Medical Receives FDA 510(k) Clearance for SCOUT® MD™ Surgical Guidance System New guidance system marks significant advancement in breast cancer care, targeting tumor location in multiple dimensions for precise excision and successful surgeries SOUTH JORDAN, Utah, Feb. 15, 2024 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a global leader of healthcare technology, has received US Food and Drug Administration (FDA) 501(k) clearance for the SCOUT® MD™ Surgical Guidance System. The release of the new guidance system demonstrates Merit’s ongoing leadership...
First Patient Enrolled in Merit Medical’s MOTION Study
First Patient Enrolled in Merit Medical’s MOTION Study SOUTH JORDAN, Utah, Jan. 16, 2024 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a leading global manufacturer and marketer of healthcare technology, today announced the successful enrollment of the first patient in its multicenter, prospective, randomized, controlled trial comparing genicular artery embolization (GAE) using Embosphere® Microspheres to corticosteroid injections for the treatment of symptomatic knee osteoarthritis (MOTION) study. Globally, more than 650 million adults are affected by osteoarthritis of...
Merit Medical Announces Projected Preliminary Unaudited Revenue for th...
Merit Medical Announces Projected Preliminary Unaudited Revenue for the Year Ended December 31, 2023 and Plans to Announce Fourth Quarter and Year End 2023 Results and Issue Fiscal Year 2024 Guidance on February 28, 2024 2023 reported preliminary unaudited revenue in the range of approximately $1.255 billion - $1.259 billion, up approximately 9.0% - 9.4% year-over-year2023 preliminary unaudited constant currency revenue* in the range of up approximately 9.6% - 9.9% year over year2023 financial results and 2024 guidance to be released February 28, 2024 * Constant currency revenue is ...
Merit Medical to Present at the J.P. Morgan 42nd Annual Healthcare Con...
Merit Medical to Present at the J.P. Morgan 42nd Annual Healthcare Conference Merit Medical Chairman and CEO Fred Lampropoulos to present on Monday, January 8 SOUTH JORDAN, Utah, Jan. 03, 2024 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a leading global manufacturer and marketer of healthcare technology, announced today that Merit Chairman and CEO, Fred Lampropoulos, is scheduled to present at the J.P. Morgan 42nd Annual Healthcare Conference on January 8, 2024, at 4:30pm PT. A live audio webcast of the conference presentation will be available on the investor sectio...
Merit Medical Announces Process for Chief Executive Officer Succession...
Merit Medical Announces Process for Chief Executive Officer Succession Planning SOUTH JORDAN, Utah, Dec. 18, 2023 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a leading global manufacturer and marketer of healthcare technology, today outlined the ongoing succession planning process for its Chief Executive Officer (CEO). Pursuant to an Amended and Restated Employment Agreement, effective June 8, 2023, Merit founder, CEO, and President, Fred Lampropoulos, will continue to serve as Merit’s CEO and President through December 31, 2025. To carry out its responsibility for ...
Merit Medical Announces Pricing of Upsized Private Offering of $650.0 ...
Merit Medical Announces Pricing of Upsized Private Offering of $650.0 Million of 3.00% Convertible Senior Notes Due 2029 SOUTH JORDAN, Utah, Dec. 06, 2023 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (Nasdaq: MMSI) (“Merit”), a leading global manufacturer and marketer of healthcare technology, announced the pricing of $650.0 million aggregate principal amount of 3.00% Convertible Senior Notes due 2029 (the “notes”) in a private placement (the “offering”) only to persons reasonably believed to be “qualified institutional buyers” pursuant to Rule 144A under the Securities Act of 1933, as...
Merit Medical Announces Proposed Private Placement of $550 Million of ...
Merit Medical Announces Proposed Private Placement of $550 Million of Convertible Senior Notes SOUTH JORDAN, Utah, Dec. 04, 2023 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (Nasdaq: MMSI) (“Merit”), a leading global manufacturer and marketer of healthcare technology, announced today that it intends to offer, subject to market conditions and other factors, $550.0 million aggregate principal amount of Convertible Senior Notes due 2029 (the “notes”) in a private placement (the “offering”) only to persons reasonably believed to be “qualified institutional buyers” pursuant to Rule 144A und...
Merit Medical Reports Results for Third Quarter Ended September 30, 20...
Merit Medical Reports Results for Third Quarter Ended September 30, 2023 Q3 2023 reported revenue of $315.2 million, up 9.8% year-over-yearQ3 2023 constant currency revenue* up 9.7% year over yearQ3 2023 constant currency revenue, organic* up 7.1% year-over-yearQ3 2023 GAAP operating margin of 11.1%, compared to 6.5% in Q3 2022Q3 2023 non-GAAP operating margin* of 18.3%, compared to 16.1% in Q3 2022Q3 2023 GAAP EPS $0.44, compared to $0.27 in Q3 2022Q3 2023 non-GAAP EPS* of $0.75, compared to $0.64 in Q3 2022Raises fiscal year 2023 financial guidance * Constant currency revenu...
Merit Medical Launches Expanded Maestro® Microcatheter Line
Merit Medical Launches Expanded Maestro® Microcatheter Line New multipurpose microcatheter length complements Merit’s radial-first legacy SOUTH JORDAN, Utah, Oct. 10, 2023 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a leading global manufacturer and marketer of healthcare technology, today announced the expansion of its Maestro Microcatheter product line to now include a new longer length for radial embolization procedures. The Maestro is part of a comprehensive offering of embolotherapy solutions, which includes Embosphere® Microspheres, the most widely studi...
Merit Medical Systems to Announce Third Quarter 2023 Results on Octobe...
Merit Medical Systems to Announce Third Quarter 2023 Results on October 26, 2023 SOUTH JORDAN, Utah, Oct. 05, 2023 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a leading global manufacturer and marketer of healthcare technology, announced today that it will release its financial results for the quarter ended September 30, 2023, after the close of the stock market on Thursday, October 26, 2023. Merit will hold its investor conference call on the same day (Thursday, October 26, 2023) at 5:00 p.m. Eastern (4:00 p.m. Central, 3:00 p.m. Mountain, and 2:00 p.m. Pacific). ...
- Dave Nicoski
- Ross LaDuke
Vermilion Short Shots: Technically Vulnerable Stocks
Short Shots is a collection of technically vulnerable charts culled from the Negative Inflecting and Toppy columns within our Weekly Compass report or from various technical screening processes. The charts contained in this report have developed concerning technical patterns that suggest further price deterioration is likely. For these reasons Short Shots can also be a great source of ideas for investors interested in short-selling candidates.
TGI TRIUMPH GROUP INC.
TFX TELEFLEX INCORPORATED
STAA STAAR SURGICAL CO.
SNE. SONY CORP. (ADS)
SLAB SILICON LABORATORIES INC.
SEE SEALED AIR CORPORATION
SEDG SOLAREDGE TECHNOLOGIES INC.
RVNC REVANCE THERAPEUTICS INC.
RMD RESMED INC.
MMSI MERIT MEDICAL SYSTEMS INC.
KHC KRAFT HEINZ COMPANY
ICUI ICU MEDICAL INC.
HMC HARMONIC
GIS GENERAL MILLS INC.
DIOD DIODES INCORPORATED
BLFS BIOLIFE SOLUTIONS INC
AVD AMERICAN VANGUARD
ODEL.N0000 ODEL PLC
ENPH ENPHASE ENERGY INC.
FMC FMC CORPORATION
VMI VALMONT INDUSTRIES INC.
PI IMPINJ INC.
ST SENSATA TECHNOLOGIES HOLDING PLC
GTES GATES INDUSTRIAL CORP
TMDX TRANSMEDICS GROUP
CTVA CORTEVA INC
KROS KEROS THERAPEUTICS
LAC. LITHIUM AMERICAS CORP
TMCI TREACE MED CONCEPTS INC
PLL PIEDMONT LITHIUM INC
Merit Medical’s WRAPSODY™ Arteriovenous Access Efficacy (WAVE) Pivotal...
Merit Medical’s WRAPSODY™ Arteriovenous Access Efficacy (WAVE) Pivotal Study Completes Enrollment SOUTH JORDAN, Utah, Aug. 03, 2023 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a leading global manufacturer and marketer of healthcare technology, today announced the completion of enrollment in its WRAPSODY Arteriovenous Access Efficacy (WAVE) pivotal study. Merit’s WAVE study is a prospective, randomized, controlled, multicenter study comparing the Merit WRAPSODY Cell-Impermeable Endoprosthesis (CIE) to percutaneous transluminal angioplasty for treatment of stenosis/occl...
Merit Medical Reports Results For Second Quarter June 30, 2023
Merit Medical Reports Results For Second Quarter June 30, 2023 Q2 2023 reported revenue of $320.1 million, up 8.5% year-over-yearQ2 2023 constant currency revenue* up 9.4% year over yearQ2 2023 constant currency revenue, organic* up 9.1% year-over-yearQ2 2023 GAAP operating margin of 9.0%, compared to 7.9% in Q2 2022Q2 2023 non-GAAP operating margin* of 19.9%, compared to 19.1% in Q2 2022Q2 2023 GAAP EPS $0.35, compared to $0.27 in Q2 2022Q2 2023 non-GAAP EPS* of $0.81, compared to $0.73 in Q2 2022 * Constant currency revenue; constant currency revenue, organic; non-GAAP EPS; non-GAAP net...
Merit Medical Systems to Announce Second Quarter 2023 Results On July ...
Merit Medical Systems to Announce Second Quarter 2023 Results On July 25, 2023 SOUTH JORDAN, Utah, July 06, 2023 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a leading global manufacturer and marketer of healthcare technology, announced today that it will release its financial results for the quarter ended June 30, 2023, after the close of the stock market on Tuesday, July 25, 2023. Merit will hold its investor conference call on the same day (Tuesday, July 25, 2023) at 5:00 p.m. Eastern (4:00 p.m. Central, 3:00 p.m. Mountain, and 2:00 p.m. Pacific). To access the...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.